ES2643646T3 - Vectores de vacuna y métodos para potenciar las respuestas inmunitarias - Google Patents
Vectores de vacuna y métodos para potenciar las respuestas inmunitarias Download PDFInfo
- Publication number
- ES2643646T3 ES2643646T3 ES11735230.2T ES11735230T ES2643646T3 ES 2643646 T3 ES2643646 T3 ES 2643646T3 ES 11735230 T ES11735230 T ES 11735230T ES 2643646 T3 ES2643646 T3 ES 2643646T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- polypeptide
- hmgb1
- vaccine vector
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims description 146
- 229960005486 vaccine Drugs 0.000 title claims description 132
- 230000028993 immune response Effects 0.000 title claims description 39
- 238000000034 method Methods 0.000 title description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 200
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 199
- 229920001184 polypeptide Polymers 0.000 claims description 197
- 108700010013 HMGB1 Proteins 0.000 claims description 88
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 85
- 101150021904 HMGB1 gene Proteins 0.000 claims description 85
- 230000000890 antigenic effect Effects 0.000 claims description 67
- 108091033319 polynucleotide Proteins 0.000 claims description 57
- 102000040430 polynucleotide Human genes 0.000 claims description 57
- 239000002157 polynucleotide Substances 0.000 claims description 57
- 241000700605 Viruses Species 0.000 claims description 31
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 241000712461 unidentified influenza virus Species 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 23
- 230000003308 immunostimulating effect Effects 0.000 claims description 21
- 108091005703 transmembrane proteins Proteins 0.000 claims description 20
- 102000035160 transmembrane proteins Human genes 0.000 claims description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 18
- 230000002163 immunogen Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 101150013553 CD40 gene Proteins 0.000 claims description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000005875 antibody response Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 230000002787 reinforcement Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 1
- 102000055207 HMGB1 Human genes 0.000 description 73
- 241000287828 Gallus gallus Species 0.000 description 28
- 235000013330 chicken meat Nutrition 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 17
- 101710154606 Hemagglutinin Proteins 0.000 description 16
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 16
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 16
- 101710176177 Protein A56 Proteins 0.000 description 16
- 239000000185 hemagglutinin Substances 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 244000063299 Bacillus subtilis Species 0.000 description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000037797 influenza A Diseases 0.000 description 11
- 241000894007 species Species 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 244000052769 pathogen Species 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 241000712431 Influenza A virus Species 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 244000144977 poultry Species 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 229960001212 bacterial vaccine Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 101150101706 cotB gene Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 101150012518 lamB gene Proteins 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229960000268 spectinomycin Drugs 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 101100398653 Yersinia pestis lamB1 gene Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000053637 human HMGB1 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 101150048352 mazF gene Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29709810P | 2010-01-21 | 2010-01-21 | |
| US297098P | 2010-01-21 | ||
| PCT/US2011/022062 WO2011091255A1 (en) | 2010-01-21 | 2011-01-21 | Vaccine vectors and methods of enhancing immune responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2643646T3 true ES2643646T3 (es) | 2017-11-23 |
Family
ID=44307229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11735230.2T Active ES2643646T3 (es) | 2010-01-21 | 2011-01-21 | Vectores de vacuna y métodos para potenciar las respuestas inmunitarias |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8956618B2 (esLanguage) |
| EP (1) | EP2525817B8 (esLanguage) |
| JP (3) | JP6242050B2 (esLanguage) |
| KR (1) | KR101638661B1 (esLanguage) |
| CN (1) | CN102811734B (esLanguage) |
| AU (1) | AU2011207331C1 (esLanguage) |
| CA (1) | CA2787661C (esLanguage) |
| CL (1) | CL2012002016A1 (esLanguage) |
| CO (1) | CO6561819A2 (esLanguage) |
| DK (1) | DK2525817T3 (esLanguage) |
| EA (1) | EA023058B1 (esLanguage) |
| ES (1) | ES2643646T3 (esLanguage) |
| HU (1) | HUE037157T2 (esLanguage) |
| MX (1) | MX341775B (esLanguage) |
| NO (1) | NO2525817T3 (esLanguage) |
| NZ (1) | NZ601609A (esLanguage) |
| PL (1) | PL2525817T3 (esLanguage) |
| PT (1) | PT2525817T (esLanguage) |
| UA (1) | UA110024C2 (esLanguage) |
| WO (1) | WO2011091255A1 (esLanguage) |
| ZA (1) | ZA201205824B (esLanguage) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2704422C (en) * | 2007-11-01 | 2019-09-24 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| DK2525817T3 (en) | 2010-01-21 | 2017-10-02 | Univ Arkansas | Vaccine vectors and methods for enhancing immune responses |
| NZ604412A (en) | 2010-06-09 | 2015-01-30 | Univ Arkansas | Vaccine and methods to reduce campylobacter infection |
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| EP2646050B1 (en) | 2010-12-02 | 2016-09-07 | mAB-Factory GmbH | Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections |
| EA030929B1 (ru) | 2013-02-14 | 2018-10-31 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас | КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria |
| HK1219045A1 (zh) | 2013-03-15 | 2017-03-24 | The Board Of Trustees Of The University Of Arkansas | 增强对肠道病原体免疫应答的组合物和方法 |
| CN105399808B (zh) * | 2015-11-23 | 2019-05-10 | 青岛农业大学 | 一种许氏平鮋免疫增强蛋白hmgb1基因及编码蛋白和应用 |
| BR112018072592A2 (pt) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| US11744875B2 (en) | 2019-07-12 | 2023-09-05 | Op-T Llc | Peptides and methods for treating disease |
| EP4135742A2 (en) | 2020-04-17 | 2023-02-22 | Op-T Llc | Bioactive peptides and methods of use thereof |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3415145B2 (ja) | 1991-03-05 | 2003-06-09 | ザ ウエルカム ファウンデーション リミテッド | 弱毒化細菌における組換えタンパク質の発現 |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| KR100283541B1 (ko) | 1991-10-25 | 2001-03-02 | 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 | 신규 사이토킨 |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| EP0659086B1 (en) | 1992-09-04 | 1998-11-11 | The University of Saskatchewan | Novel bacterial vaccines using vaccine strains of pathogenic bacteria |
| AU1059095A (en) | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| EP0812206B1 (en) | 1995-03-01 | 2002-07-10 | Immunex Corporation | Cd40 binding protein for stimulating an immune response |
| ES2214541T3 (es) | 1995-06-07 | 2004-09-16 | Immunex Corporation | Muteina de cd40l. |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6306387B1 (en) | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
| US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
| AU2004199A (en) | 1997-12-19 | 1999-07-12 | Immunex Corporation | Method for reducing susceptibility to hiv infection |
| GB9806449D0 (en) | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
| IT1299583B1 (it) | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
| DK1108034T3 (da) | 1998-09-04 | 2008-11-10 | Emergent Product Dev Uk Ltd | Svækkede salmonella SPI2-mutanter som antigenbærere |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| AU3966200A (en) | 1999-04-16 | 2000-11-02 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| EP1067194A1 (en) | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| AU1084901A (en) | 1999-10-14 | 2001-04-23 | Martha S. Hayden-Ledbetter | Dna vaccines encoding antigen linked to a domain that binds cd40 |
| ES2222152T3 (es) | 1999-12-28 | 2005-02-01 | Akzo Nobel N.V. | Vacuna con las salmonellas que no inducen anticuerpos que reaccionan con la flagelina o los flagelos. |
| US7371392B2 (en) | 2000-02-02 | 2008-05-13 | The United States Of America As Represented By The Department Of Health And Human Services | Cd40 ligand adjuvant for respiratory syncytial virus |
| DE60112413T2 (de) | 2000-03-17 | 2006-06-01 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Ssa inaktivierte salmonella impfstoffe |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| US20030165538A1 (en) | 2000-06-26 | 2003-09-04 | Maxygen Incorporated | Methods and compositions for developing spore display systems for medicinal and industrial applications |
| WO2002036769A2 (en) | 2000-10-31 | 2002-05-10 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| CZ20033402A3 (cs) | 2001-05-15 | 2004-10-13 | Northáshore@Longáislandájewisháresearcháinstitute | Použití fragmentů HMG jako protizánětlivých činidel |
| CA2447593C (en) | 2001-05-15 | 2014-07-08 | Ortho-Mcneil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| ITMI20011986A1 (it) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| DE50212280D1 (de) | 2001-12-19 | 2008-06-26 | Alcedo Biotech Gmbh | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren |
| US6923958B2 (en) | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
| EP1499191B1 (en) | 2002-04-15 | 2012-05-09 | Washington University in St. Louis | Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
| US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| WO2004046338A2 (en) | 2002-11-20 | 2004-06-03 | North Shore-Long Island Jewish Research Institute | Use of hmgb polypeptides for increasing immune responses |
| US20040141948A1 (en) | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
| US20040156851A1 (en) | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
| WO2004046345A2 (en) | 2002-11-20 | 2004-06-03 | Critical Therapeutics, Inc. | Use of hmgb fragments as anti-inflammatory agents |
| US20060014248A1 (en) | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20050181994A1 (en) | 2003-01-06 | 2005-08-18 | Xencor, Inc. | Novel variants of CD40L protein |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| WO2005035570A2 (en) | 2003-10-10 | 2005-04-21 | Xencor, Inc. | Variants of cd40l protein |
| EP1720905A2 (en) | 2003-12-11 | 2006-11-15 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
| JP2008508855A (ja) | 2004-04-27 | 2008-03-27 | インターツェル・アクチェンゲゼルシャフト | Ｔｄ抗原 |
| WO2005113598A2 (en) | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
| US20080305120A1 (en) * | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| US20080075728A1 (en) | 2004-07-20 | 2008-03-27 | Walter Newman | Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation |
| EP1809737B9 (en) | 2004-10-07 | 2011-10-05 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| GB0423681D0 (en) | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
| EP1831259A2 (en) | 2004-12-21 | 2007-09-12 | Vaxinnate Corporation | Compositions of influenza viral proteins and methods of use thereof |
| WO2006105972A1 (en) | 2005-04-07 | 2006-10-12 | Universite Libre De Bruxelles | Transgenic organism expressing cd40l and uses thereof |
| US20060286074A1 (en) | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
| WO2007011606A2 (en) | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| BRPI0616978A2 (pt) | 2005-10-07 | 2011-07-05 | Proyecto Biomedicina Cima Sl | combinação imuno-estimulante para a profilaxia e tratamento de hepatite c, sua utilização, composição farmacêutica que a contém, kit para sua administração, método para produzir uma resposta imune e vacina contra o vìrus da hepatite c |
| AU2006311752A1 (en) | 2005-11-07 | 2007-05-18 | Sidney Kimmel Cancer Center | CD40 ligand fusion protein vaccine |
| WO2007054658A1 (en) | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
| WO2007130725A2 (en) | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| WO2007106073A2 (en) | 2006-03-02 | 2007-09-20 | University Of Massachusetts | Modified pathogens for use as vaccines |
| US9439959B2 (en) * | 2006-07-27 | 2016-09-13 | Takeda Vaccines, Inc. | Chimeric influenza virus-like particles |
| US8564612B2 (en) * | 2006-08-04 | 2013-10-22 | Apple Inc. | Deep pixel pipeline |
| JP2010500034A (ja) * | 2006-08-09 | 2010-01-07 | メッドイミューン バクシーンズ，インコーポレイティド | インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体 |
| KR101460551B1 (ko) * | 2006-09-18 | 2014-11-18 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역 반응을 향상시키는 조성물 및 방법 |
| EP2139913A4 (en) | 2007-03-08 | 2011-09-21 | Mayo Foundation | INTRODUCTION OF IMMUNE-MEDIUM TUMOR CELL DEOD |
| EP2152730A4 (en) * | 2007-05-02 | 2011-08-03 | Univ Emory | ENLARGEMENT OF GLYCOPROTEININCORPORATION IN VIRUSUAL PARTICLES |
| AU2008318615A1 (en) | 2007-10-30 | 2009-05-07 | Texas A&M University System | Compositions and methods of enhancing immune responses to flagellated bacterium |
| CA2704422C (en) | 2007-11-01 | 2019-09-24 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| DK2525817T3 (en) | 2010-01-21 | 2017-10-02 | Univ Arkansas | Vaccine vectors and methods for enhancing immune responses |
| NZ604412A (en) | 2010-06-09 | 2015-01-30 | Univ Arkansas | Vaccine and methods to reduce campylobacter infection |
| MX2014005754A (es) | 2011-11-11 | 2015-02-10 | Nutrition Physiology Company Llc | Bacterias de ácido láctico y su uso como suplementos dietéticos para aves de corral. |
-
2011
- 2011-01-21 DK DK11735230.2T patent/DK2525817T3/en active
- 2011-01-21 UA UAA201210026A patent/UA110024C2/ru unknown
- 2011-01-21 CN CN201180006369.8A patent/CN102811734B/zh active Active
- 2011-01-21 US US13/574,504 patent/US8956618B2/en active Active
- 2011-01-21 MX MX2012008506A patent/MX341775B/es active IP Right Grant
- 2011-01-21 AU AU2011207331A patent/AU2011207331C1/en active Active
- 2011-01-21 NO NO11735230A patent/NO2525817T3/no unknown
- 2011-01-21 JP JP2012550153A patent/JP6242050B2/ja active Active
- 2011-01-21 CA CA2787661A patent/CA2787661C/en active Active
- 2011-01-21 EA EA201290675A patent/EA023058B1/ru not_active IP Right Cessation
- 2011-01-21 EP EP11735230.2A patent/EP2525817B8/en active Active
- 2011-01-21 ES ES11735230.2T patent/ES2643646T3/es active Active
- 2011-01-21 NZ NZ601609A patent/NZ601609A/en not_active IP Right Cessation
- 2011-01-21 WO PCT/US2011/022062 patent/WO2011091255A1/en not_active Ceased
- 2011-01-21 HU HUE11735230A patent/HUE037157T2/hu unknown
- 2011-01-21 PL PL11735230T patent/PL2525817T3/pl unknown
- 2011-01-21 KR KR1020127021697A patent/KR101638661B1/ko active Active
- 2011-01-21 PT PT117352302T patent/PT2525817T/pt unknown
-
2012
- 2012-07-19 CO CO12122137A patent/CO6561819A2/es not_active Application Discontinuation
- 2012-07-20 CL CL2012002016A patent/CL2012002016A1/es unknown
- 2012-08-02 ZA ZA2012/05824A patent/ZA201205824B/en unknown
-
2015
- 2015-02-16 US US14/623,105 patent/US9913893B2/en active Active
-
2016
- 2016-03-08 JP JP2016044306A patent/JP2016117757A/ja active Pending
-
2017
- 2017-12-05 JP JP2017233454A patent/JP6687585B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2643646T3 (es) | Vectores de vacuna y métodos para potenciar las respuestas inmunitarias | |
| ES2968398T3 (es) | Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria | |
| KR102239207B1 (ko) | 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법 | |
| KR20100075843A (ko) | 인플루엔자 단백질 조성물 및 그 제조 및 사용 방법 | |
| JP5766894B2 (ja) | ワクチン増強剤としてのαチモシンペプチド | |
| CN103517713A (zh) | 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽 | |
| JP2013516469A (ja) | 高齢者に保護免疫を提供するための方法及び組成物 | |
| RU2776479C1 (ru) | Живая пробиотическая вакцина, содержащая консервативные эпитопы вируса гриппа А (LAH+4M2e), для профилактики гриппозной инфекции | |
| BR112012018027B1 (pt) | Vetores de vacina e métodos de aperfeiçoamento de respostas imunes | |
| KR20170010717A (ko) | 점막부착성 고분자 아주번트기반 인플루엔자 백신 | |
| HK1176279B (en) | Vaccine vectors and methods of enhancing immune responses | |
| HK1176279A (en) | Vaccine vectors and methods of enhancing immune responses |